[ad_1]
EyePoint Pharmaceuticals EYPT reported its Q3 earnings results on Wednesday, November 2, 2022 at 07:00 AM.
Here’s what investors need to know about the announcement.
Earnings
EyePoint Pharmaceuticals beat estimated earnings by 30.0%, reporting an EPS of $-0.49 versus an estimate of $-0.7.
Revenue was up $953 thousand from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.0 which was followed by a 2.84% increase in the share price the next day.
Here’s a look at EyePoint Pharmaceuticals’s past performance:
| Quarter | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.52 | -0.58 | -0.53 | -0.40 |
| EPS Actual | -0.52 | -0.56 | -0.59 | -0.58 |
| Revenue Estimate | 10.87M | 9.89M | 9.80M | 9.84M |
| Revenue Actual | 11.56M | 9.29M | 11.54M | 9.06M |
To track all earnings releases for EyePoint Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
[ad_2]
Image and article originally from www.benzinga.com. Read the original article here.